Latest Clinical Data News

AdAlta has engaged specialist advisors to streamline US FDA regulatory processes for its CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients.

OncoSil Medical’s interim OSPREY Registry data show strong safety and promising survival outcomes for its targeted radiotherapy device in unresectable locally advanced pancreatic cancer, surpassing historical benchmarks.

AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.

Pacific Edge edges closer to a Medicare breakthrough with a draft Local Coverage Determination proposing coverage for its Cxbladder Triage and Triage Plus tests, potentially unlocking reimbursement for over 66 million US patients.

Syntara Limited offers existing shareholders a discounted share purchase plan to raise about $2 million, following a recent $8 million institutional placement to fund clinical trials and licensing.

Vectus Biosystems appoints Dr Tara Speranza as CEO and CTO to accelerate development of lead fibrosis drug VB0004 with performance-linked incentives.

Anteris Technologies has treated the first US patients in its global PARADIGM trial, marking a key milestone in testing its DurAVR transcatheter heart valve against established devices.

Noxopharm is gearing up for a pivotal pre-IND meeting with the US FDA, enlisting global CRO Novotech to sharpen its regulatory approach for SOF-SKN, a drug targeting autoimmune skin diseases.

Entropy Neurodynamics has bolstered its intellectual property portfolio with a new US provisional patent application for TRP-8803, following compelling Phase 2a data showing a 75% response rate in treatment-resistant IBS patients.

AdAlta has secured A$2.5 million in a strategic placement to push its lead CAR-T therapy BZDS1901 through critical US FDA regulatory steps and establish Australian manufacturing, building on promising clinical responses in advanced mesothelioma.

PYC Therapeutics presented Phase 1/2 data at ARVO 2026 showing encouraging safety and efficacy signals for its RNA therapies targeting rare genetic eye diseases Retinitis Pigmentosa type 11 and Autosomal Dominant Optic Atrophy.

LTR Pharma highlights SPONTAN's 5x faster absorption and validated safety, backed by over 1,000 Australian prescriptions and strategic partnerships as it targets FDA approval and US market entry.